Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
  • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Definitions

• This invention relates to novel benzamides, to pharmaceutical compositions containing them, to processes and intermediates for their preparation, and to their use in the treatment of psychosis.
• South African Pat. No. 80/0160 discloses inter alia compounds of formula (A), and their pharmaceutically acceptable salts: ##STR2## wherein R a is a lower alkyl, trifluoromethyl or cyano group or an atom of chlorine, bromine of fluorine. Such compounds are described as having neuroleptic properties.
• R c and R d are the same or different and are hydrogen, halogen, CF 3 , C 2-7 acylamino, or amino, aminocarbonyl or aminosulphone optionally substituted by one or two C 1-6 alkyl groups, C 1-6 alkylsulphone or nitro;
• R e is hydrogen or C 1-6 alkyl
• R f is C 1-7 alkyl or a group --(CH 2 ) s R g where s is 0 to 2 and R g is a C 3-8 cycloalkyl group, or a group --(CH 2 ) t R h where t is 1 or 2 and R h is C 2-5 alkenyl or a phenyl group optionally substituted by one or two substituents selected from C 1-6 alkyl, C 1-4 alkoxy, trifluoromethyl and halogen; and
• n, p and q are independently 0 to 2.
• the benzamides of formula (B) are described as dopamine antagonists and are useful in the treatment of emesis. They are also described, depending on their balance between peripheral and central action on the nervous system, as being useful in the treatment of disorders relating to impaired gastro-intestinal motility, such as retarded gastric emptying, dyspepsia, flatulence, oesphagal reflux and peptic ulcer, and/or in the treatment of disorders of the central nervous system, such as psychosis.
• benzamides have now been discovered which fall within the scope of the aforementioned European patent publication and U.S. patent and which have a norgranatyl side chain containing a p-methyl, p-chloro or p-fluorobenzyl substituent on the bridgehead nitrogen atom.
• Such benzamides have particularly advantageous anti-psychotic activity. They also have a low level of side effects, such as extrapyramidal effects, and a prolonged duration of action. They are therefore useful in the treatment of psychosis.
• the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: ##STR4## wherein X is methoxy or ethoxy, Y is amino or C 1-6 alkanoylamino, Z is hydrogen, chloro or bromo and R 1 is methyl, chloro or fluoro.
• X is methoxy
• Y is C 1-6 alkanoylamino, it is preferably acetylamino. However, Y is preferably amino.
• Z is bromo or, in particular, chloro.
• formula (I) are the compounds; 4-amino-5-chloro-2-methoxy-N-(3' ⁇ -[9'-(4-methylbenzyl)-9'-azabicyclo-[3.3.1]-nonyl])benzamide; 4-amino-5-chloro-2-methoxy-N-(3' ⁇ -[9'-(4-chlorobenzyl)-9'-azabicyclo-[3.3.1]-nonyl])benzamide; 4-amino-5-chloro-2-methoxy-N-(3' ⁇ -[9'-(4-fluorobenzyl)-9'-azabicyclo-[3.3.1]-nonyl])benzamide; 4-amino-5-bromo-2-methoxy-N-(3' ⁇ -[9'-(4-fluorobenzyl)-9'-azabicyclo-[3.3.1]-nonyl])benzamide; 4-acetylamino-5-chloro-2-meth
• the most preferred compounds of formula (I) are the compounds, wherein R 1 is fluoro and their pharmaceutically acceptable salts and solvates.
• the pharmaceutically acceptable salts of the compound of formula (I) include acid addition salts with conventional pharmaceutically acceptable acids, such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acid.
• the solvates of the compounds of formula (I) include hydrates.
• the invention also provides a process of preparing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, which comprises reacting a compound of formula (II): ##STR5## wherein X and Z are as defined hereinbefore, R 2 is Y or a protected amino group, and Q 1 is a leaving group, with a compound of formula (III): ##STR6## wherein R 3 is a protecting group or p-methylbenzyl, p-chlorobenzyl or p-fluorobenzyl; in the case where R 2 is a protected amino group, removing the protecting group; in the case where R 3 is a protecting group, removing the protecting group and reacting the secondary amine with a compound of formula (IV): ##STR7## wherein Q 2 is a leaving group, M is CO or CH 2 and R 1 is as hereinbefore defined, and when M is CO, reducing the resulting N-benzoyl compound to give the corresponding N-benzyl compound; in the case
• the leaving group Q 1 is a group that is readily displaceable by a nucleophilic primary amine such that an amido linkage can be formed between the compounds of formula (II) and (III). It may be displaced in the form of an anion or in the form of a condensation by-product.
• Examples of the leaving group Q 1 include hydroxy, halogen, acyloxy and activated hydrocarbyloxy.
• the reaction is preferably carried out in an inert non-hydroxylic solvent, such as benzene, toluene, dichloromethane, dimethylformamide or diethyl ether in the presence of a dehydrating catalyst, such as a carbodiimide, for example dicyclohexylcarbodiimide.
• a dehydrating catalyst such as a carbodiimide, for example dicyclohexylcarbodiimide.
• the reaction may be carried out at any non-extreme temperature, such as -10° to 100° C., for example, 0° to 80° C.
• the reaction is preferably carried out at non-extreme temperatures in an inert non-hydroxylic solvent, such as benzene, toluene, dichloromethane or diethyl ether. It is also preferably carried out in the presence of an acid acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, a number of which can also function as the solvent.
• the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate.
• the reaction is preferably carried in substantially the same manner as if the leaving group were hydroxy.
• the reaction is preferably carried out in an inert solvent, such as methylene chloride, at a non-extreme temperature in the presence of an acid acceptor, such as triethylamine.
• an inert solvent such as methylene chloride
• the reaction is preferably carried out in an inert polar solvent, such as dimethylformamide. It is also preferred that the activated hydrocarbyloxy group is a pentachlorophenyl ester and that the reaction is carried at ambient temperature.
• Q 1 is hydroxy, chloro or, in particular, C 1-4 alkoxycarbonyloxy, such as ethoxycarbonyloxy.
• a protected amino group for R 2 is an amino group substituted by a protecting group.
• protecting groups include C 1-6 alkanoyl groups, for example acetyl, propionyl, n- and iso-butyryl and 2,2-dimethylpropanoyl, or benzoyl optionally substituted in the phenyl ring by one or two substituents selected from C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl and nitro, or C 1-4 alkoxycarbonyl, for example tert-butoxycarbonyl.
• R 3 examples include those for R 2 , when a protected amino group. Additionally, R 3 may also be a benzyl group optionally substituted as defined above for a benzoyl protecting group.
• the removal of the protecting group R 3 and/or the removal of the protecting group from the protected amino group R 2 are/is achieved in accordance with known procedures.
• the removal of a C 1-6 alkanoyl or an optionally substituted benzoyl protecting group may be achieved by acid or base hydrolysis, preferably at an elevated temperature.
• the removal of a C 1-4 alkoxycarbonyl protecting group may be achieved with trifluoroacetic acid.
• the removal of an optionally substituted benzyl protecting group may be achieved by hydrogenolysis, for example using a transition metal catalyst, such as platinum or palladium on charcoal, at or above atmospheric pressure in a solvent, such as ethanol, at ambient temperature.
• R 2 is a protected amino group and R 3 is a protecting group
• the protecting groups are independently removable.
• one of the protecting groups may be a C 1-4 alkanoyl group, such as an acetyl group, removable by acid or base hydrolysis and the other may be a benzyl group removable by catalytic hydrogenolysis.
• R 3 is benzyl and R 2 is C 1-4 alkanoylamino, such as acetylamino.
• R 2 is a protected amino group and R 3 is a protecting group
• the protecting group R 3 is removed and the resulting secondary amine reacted with a compound of formula (IV) prior to removal of the protecting group of the protected amino group R 2 .
• the leaving group Q 2 of formula (IV) is a group that is readily displaceable by a nucleophilic secondary amine such that a tertiary amine or amide can be formed.
• Examples of such leaving groups when M is CH 2 , include chloro, bromo, iodo, mesyloxy and tosyloxy, and, when M is CO, include the groups listed hereinbefore in regard to the leaving group Q 1 .
• Particularly preferred examples of Q 2 include chloro, bromo and iodo.
• the reaction of the secondary amine with a compound of formula (IV), wherein M is CH 2 may be carried out under conventional aralkylation conditions, for example, in an inert solvent, such as dimethyl formamide in the presence of an acid acceptor, such as potassium carbonate. Generally, the reaction is carried out at a non-extreme temperature, such as at ambient temperature or at a slightly elevated temperature.
• the reaction of the secondary amine with a compound of formula (IV), wherein M is CO may be carried out under conventional aroylation conditions, for example, the conditions described hereinbefore for the reaction between compounds of formula (II) and (III).
• the resulting N-benzoyl compound may be reduced to give the corresponding N-benzyl compound in accordance with known reducing procedures, for example by reduction with lithium aluminium hydride or diborane.
• the reaction with the benzoyl derivative of formula (IV) and the subsequent reduction can conveniently be carried out in a single operation using sodium cyanoborohydride under weakly acidic conditions.
• R 2 is an amino group or a protected amino group and R 3 is p-methylbenzyl, p-chlorobenzyl or in particular p-fluorobenzyl. In this way, the additional steps of removing the protecting group R 3 and reacting the resulting secondary amine with a compound of formula (IV) are avoided.
• Conversion of a compound of formula (I), wherein R 2 is amino, into a corresponding compound of formula (I), wherein R 2 is C 1-6 alkanoylamino may be carried out in accordance with known procedures, for example by reaction with an acylating derivative, such as the anhydride or acid halide, of the appropriate C 1-6 alkanoic acid.
• an acylating derivative such as the anhydride or acid halide
• the compounds of formula (III) can be prepared by reduction of a compound of formula (V): ##STR8## wherein R 3 is hereinbefore defined.
• the reduction is carried out with an alkali metal, such as sodium, and a C 1-6 alkanol, such as amyl alcohol.
• an alkali metal such as sodium
• a C 1-6 alkanol such as amyl alcohol
• Reducing agents which give mixtures of ⁇ - and ⁇ -isomers may also be used as the desired ⁇ -isomer can be separated from the mixture by conventional techniques. However, any such separation is preferably carried out later in the synthesis when the isomers are easier to handle. It is particularly preferred that the separation is carried out on the product of the reaction between a compound of formula (II), wherein R 2 is a protected amino group, such as C 1-6 alkanoylamino, e.g. acetylamino, and a compound of formula (III).
• the compounds of formula (V) can be prepared by reaction of a compound of formula (VI): ##STR9## wherein R 3 is as hereinbefore defined, with hydroxylamine.
• R 3 is as defined, with glutaric dialdehyde and 1,3-acetone dicarboxylic acid.
• compounds of formula (VI), wherein R 3 is a protecting group that gives rise to a carbonyl function adjacent to the nitrogen atom, such as C 1-6 alkanoyl, benzoyl optionally substituted as hereinbefore defined, or C 1-4 alkoxycarbonyl are prepared by removal of the benzyl protecting group optionally substituted as hereinbefore defined from a compound of formula (VI), wherein R 3 is so defined, and then converting the secondary amine to a compound of formula (VI), wherein R 3 is a carbonyl-containing protecting group as defined.
• the compounds of formula (VII) are known or can be prepared analogously to the preparation of known compounds.
• the present invention provides an alternative process for the preparation of a compound of formula (III), which comprises the removal of the protecting group from a compound of formula (VIII): ##STR10## wherein R 1 is as hereinbefore defined and one of R 4 and R 5 is a monovalent protecting group and the other is hydrogen or R 4 and R 5 together are a divalent protecting group.
• the protecting group is such that its removal can be carried out under conditions that will not significantly affect any other part of the compound. In particular, there should be no significant removal of the p-substituted benzyl moiety.
• a particularly preferred example of a monovalent protecting group is C 1-6 alkanoyl, such as acetyl, which can be removed in the desired manner by acid or base hydrolysis.
• An example of a divalent protecting group is phthaloyl which can be removed in the desired manner by base hydrolysis.
• the compounds of formula (VIII) can be prepared by reaction of a compound of formula (IX): ##STR11## wherein R 4 and R 5 are as hereinbefore defined, with a compound of formula (IV), as hereinbefore defined.
• the reaction may be carried out under conventional aralkylation conditions, for example, in an inert solvent, such as dimethylformamide, in the presence of an acid acceptor, such as potassium carbonate.
• an inert solvent such as dimethylformamide
• the compounds of formula (IX) can be prepared by hydrogenolysis of a compound of formula (X): ##STR12## wherein R 4 and R 5 are as hereinbefore defined.
• the hydrogenolysis is conveniently carried out at room temperature and atmospheric pressure using 10% palladium on charcoal.
• the compounds of formula (X) can be prepared by reacting the compound of formula (XI): ##STR13## with a reagent that will monovalently or divalently protect the primary amine.
• the present invention provides another process of preparing a compound of formula (I), wherein Z is chloro or bromo, or a pharamceutically acceptable salt or solvate thereof, which comprises chlorinating or brominating a compound of formula (XII): ##STR14## wherein X and R 2 are as defined hereinbefore and R 3 ' is hydrogen or R 3 as defined hereinbefore; in the case where R 2 is a protected amino group, removing the protecting group; in the case where R 3 ' is R 3 and is a protecting group, removing the protecting group to give a compound of formula (XII), wherein R 3 ' is hydrogen; in the case where R 3 ' is hydrogen, reacting the secondary amine with a compound of formula (IV), as hereinbefore defined, and when M is CO, reducing the resulting N-benzoyl compound to give the corresponding N-benzyl compound; in the case where R 2 is Y, optionally converting the amino group or the C 1-6 alkanoylamino group
• the chlorination or bromination is preferably carried out under acidic conditions using, for example, acetic acid.
• R 2 in formula (XII) is a protected amino group, such as C 1-6 alkanoylamino, since otherwise dichlorination or dibromination could occur.
• the present invention additionally provides a process of preparing a compound of formula (I), or a pharamceutically acceptable salt of solvate thereof, which comprises reducing a compound of formula (XIII): ##STR15## wherein X and Z and R 3 ' are as defined hereinbefore; in the case where R 3 ' is R 3 and is a protecting group, removing the protecting group to give a compound of formula (XIII), wherein R 3 ' is hydrogen; in the case where R 3 ' is hydrogen, reacting the secondary amine with a compound of formula (IV), as hereinbefore defined, and when M is CO, reducing the resulting N-benzoyl compound to give the corresponding N-benzyl compound; optionally converting the primary amino group to a C 1-6 alkanoylamino group; and optionally forming a pharmaceutically acceptable salt or solvate thereof.
• the reduction may be carried out with stannous chloride and concentrated hydrochloric acid or with hydrogen and Raney nickel.
• the present invention further provides a process of preparing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, which comprises carrying out a Hoffman degradation on a compound of formula (XIV): ##STR16## wherein X and Z and R 3 ' are as hereinbefore defined; in the case where R 3 ' is R 3 and is a protecting group, removing the protecting group to give a compound of formula (XIV), wherein R 3 ' is hydrogen; in the case where R 3 ' is hydrogen, reacting the secondary amine with a compound of formula (IV), as hereinbefore defined, and when M is CO, reducing the resulting N-benzoyl compound to give the corresponding N-benzyl compound; optionally converting the primary amino group to a C 1-6 alkanoylamino group; and optionally forming a pharmaceutically acceptable salt or solvate thereof.
• the Hoffman degradation is preferably carried out with a metal hypohalite, such as sodium hypochlorite.
• the present invention provides yet a further process of preparing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, which comprises methylating or ethylating a compound of formula (XV): ##STR17## wherein Z and R 2 and R 3 ' are as hereinbefore defined; in the case where R 2 is a protected amino group, removing the protecting group; in the case where R 3 ' is R 3 and is a protecting group, removing the protecting group to give a compound of formula (XV), wherein R 3 ' is hydrogen; in the case where R 3 ' is hydrogen, reacting the secondary amine with a compound of formula (IV), as hereinbefore defined, and when M is CO, reducing the resulting N-benzoyl compound to give the corresponding N-benzyl compound; in the case where R 2 is Y, optionally converting the amino group or the C 1-6 alkanoylamino group into the other; and optionally forming a pharmaceutically acceptable salt or solvate thereof.
• the alkylating reaction may be carried out with methyl or ethyl iodide in acetone in the presence of potassium carbonate or with dimethylsulphate in the presence of sodium hydroxide. It is preferred that R 2 in formula (XV) is a protected amino group. It is also greatly preferred that R 3 ' is R 3 and is a C 1-6 alkanoyl or benzoyl protecting group.
• O-protecting groups include those mentioned hereinbefore as protecting groups for R 2 , when a protected amino group.
• R 7 is hydroxy
• R 8 is amino or C 1-6 alkanoylamino
• R 9 is hydrogen, chloro or bromo
• M is CH 2 or CO
• R 1 is methyl, chloro or fluoro.
• V is amino or C 1-6 alkanoylamino and W is hydrogen or V and W together with the carbon atom to which they are attached are an oximino group, and R 1 is as hereinbefore defined.
• Another useful intermediate is the compound of formula (VI), wherein R 3 is p-fluorobenzyl.
• the compounds of the present invention are ⁇ -isomers, i.e. where the amide linkage joins the bicyclic system, the configuration is of formula (XVIII): ##STR20## wherein: X, Y, Z and R 1 are as hereinbefore defined.
• the intermediate compounds that can also exist in two isomeric forms are used in the ⁇ -form as well.
• the intermediate compounds can also be used in mixtures of ⁇ - and ⁇ -forms and the undesired ⁇ -isomer separated from the mixture at some stage, preferably at the stage mentioned hereinbefore, in conventional manner.
• the pharmaceutically acceptable salts of the compounds of the present invention are prepared by simple reaction of the base compound of the invention with a pharmaceutically acceptable organic or inorganic acid.
• the pharmaceutically acceptable solvates of the compounds of the present invention are prepared during the course of the preparation of the compound during its work up or during recrystallisation.
• the invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.
• compositions are prepared by admixture and are preferably adapted for oral or parenteral administration and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administerable compositions are preferred.
• Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, tabletting agents, lubricants, disintegrants and wetting agents.
• the tablets may be coated according to well known methods in the art.
• Oral liquid preparations are usually in the form of aqueous or oily suspension, solutions, emulsions, syrups or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives and flavouring or colouring agents.
• fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
• the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
• Parenteral solutions are normally prepared by dissolving the compound in the vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
• adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
• Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
• a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
• the invention further provides a method of treatment of psychosis in mammals, such as humans, which comprises the administration of an anti-psychotic effective amount of a compound of the present invention, or a pharmaceutically acceptable salt or a solvate thereof, or a pharmaceutical composition, as hereinbefore defined, to the mammal.
• a unit dose will normally contain from 0.1 to 20 mg for example 0.5 to 10 mg, of the compound of the invention.
• Unit doses will normally be administered once, twice or thrice a day such that the total daily dose is normally in the range 0.01 to 10 mg/kg per day.
• the invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition, as hereinbefore defined, for use in the treatment of disorders of the central nervous system.
• a further quantity of dilute hydrochloric acid (10 ml) was then added and the mixture stirred for a further 48 hours.
• the amine of formula (D7) is predominantly one isomer and has the 3 ⁇ -configuration.
• a solution of 4-methylbenzylamine (12 g) in dilute hydrochloric acid (5N, 20 ml) was added to glutaric dialdehyde (50%, 24 ml) in water (100 ml) with stirring.
• a solution of 1,3-acetonedicarboxylic acid (14.6 g) and sodium acetate (8.2 g) in water (100 ml) was then added and the mixture stirred for 24 hours at room temperature.
• a further quantity of dilute hydrochloric acid (5 ml) was then added and the mixture stirred for a further 48 hours.
• This amine is predominantly one isomer and has the 3 ⁇ -configuration.
• results in the following table are an illustration of the anti-psychotic activity of the present compounds as shown by Inhibition of Apormorphine Induced Climbing in the Mouse, a standard test.
• the test is based on that described by Protais, P., Constantin, J. and Schwartz J. C. (1976), Psychopharmacology, 50, 1-6.
• mice When mice are given a dose of 1 mg/kg apomorphine and then placed in an enclosed environment, such as an inverted wire cage, they are seen to climb around the walls. This behavioural phenomenon is thought to be a consequence of the stimulation of post-synaptic Dopamine (D.A.) receptors in the nucleus accumbens. Inhibition of apomorphine induced climbing is therefore indicative of post-synaptic D.A. receptor blockage in the accumbens.
• D.A. post-synaptic Dopamine
• mice Groups of 10 male CD1 mice, weighing 25-30 g were pre-treated orally with either graded doses of the test compound or vehicle, at appropriate time intervals before the subcutaneous administration of a sub-maximal dose of apomorphine (1 mg/kg). Immediately after the apomorphine injection the mice were placed in wire ⁇ climbing cages ⁇ and each animal was scored for climbing behaviour at 10 and 20 minutes post apomorphine as follows:
• ED50's and fiducial limits were calculated according to the method of Litchfield and Wilcoxon, the ED50 being the dose that produced a 50% inhibition of apomorphine-induced climbing.
• the table shows the dose for 50% inhibition at 4 hour post dosing po.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (8)

Related Child Applications (1)

Publications (1)

Family

ID=27449276

Family Applications (2)

Family Applications After (1)

Country Status (13)

Cited By (6)

Families Citing this family (11)

Citations (5)

• 1982
  • 1982-09-22 DE DE8282304981T patent/DE3275296D1/de not_active Expired
  • 1982-09-22 EP EP82304981A patent/EP0076592B1/fr not_active Expired
  • 1982-09-22 GB GB08226998A patent/GB2111479A/en not_active Withdrawn
  • 1982-09-29 FI FI823336A patent/FI823336L/fi not_active Application Discontinuation
  • 1982-09-29 CA CA000412433A patent/CA1196641A/fr not_active Expired
  • 1982-09-29 GR GR69400A patent/GR77668B/el unknown
  • 1982-09-29 NZ NZ202031A patent/NZ202031A/en unknown
  • 1982-09-29 PT PT75620A patent/PT75620B/pt unknown
  • 1982-09-30 US US06/432,028 patent/US4472413A/en not_active Expired - Fee Related
  • 1982-09-30 AU AU88897/82A patent/AU8889782A/en not_active Abandoned
  • 1982-09-30 NO NO823301A patent/NO823301L/no unknown
  • 1982-09-30 ES ES516133A patent/ES8403122A1/es not_active Expired
  • 1982-09-30 DK DK435082A patent/DK435082A/da not_active Application Discontinuation
• 1983
  • 1983-06-01 ES ES522940A patent/ES522940A0/es active Granted
  • 1983-09-09 US US06/530,513 patent/US4560757A/en not_active Expired - Fee Related
• 1984
  • 1984-11-02 ES ES537358A patent/ES537358A0/es active Granted
  • 1984-11-07 ES ES537466A patent/ES537466A0/es active Granted
  • 1984-11-07 ES ES537467A patent/ES537467A0/es active Granted
• 1985
  • 1985-08-22 ES ES546355A patent/ES8608518A1/es not_active Expired

Patent Citations (6)

Also Published As

Similar Documents

Legal Events